Food, Drugs, Healthcare, Life Sciences

The Dutch government has announced a significant shift in healthcare regulation, moving away from a fragmented prohibition on profit distribution toward a uniform 'cap-and-conditions' regime that will apply to all healthcare and youth aid providers. This new approach permits profit distribution up to a maximum percentage of invested capital, but only under strict conditions including quality standards, financial health requirements, and enhanced governance measures. The proposed changes also introduce tight

Leadership advisor Tune Hein shares exclusive insights from his five-year experience as an internal specialist at Novo Nordisk during the launch of Wegovy, one of the pharmaceutical industry's most significant obesity drug introductions. What are the 10 core beliefs that propelled Novo Nordisk to become one of the world's most valuable companies, and how did their unconventional approach to scaling, management, and organizational structure drive their success in the competitive obesity drug market?

Arthur Cox's Life Sciences Outlook 2026 examines critical regulatory developments and strategic opportunities shaping Ireland's life sciences sector. The publication explores Ireland's EU Council Presidency and its potential impact on advancing key legislative initiatives including the Biotech Act I and medical device reforms. Industry leaders will find comprehensive analysis spanning pharmaceutical compliance, medtech regulation, data governance, M&A activity, and environmental considerations.